Gb Sciences Addresses Growing Need for Anxiety and Depression Medications With Non-Psychedelic, Kava-Based Formulations
12 déc. 2022 07h00 HE
|
Gb Sciences
LAS VEGAS, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is addressing the growing need for anxiety...
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting
07 déc. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
Improvement in cognitive and physical functioning, measured by the CPFQ patient-rated scale, starting at week 1 and sustained over 12 months Improvement in disability, measured by the SDS, starting...
Psychiatric Times Announces the Addition of the Anxiety and Depression Association of America to its Strategic Alliance Partnership Program
06 déc. 2022 14h15 HE
|
Psychiatric Times™
CRANBURY, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Psychiatric Times™, the #1 psychiatric publication in the United States, today announced that it has added the Anxiety and Depression Association of...
Warning Signs & What to Look for: Anxiety and Depression in Childhood - A Free Webinar from the Brain & Behavior Research Foundation
28 nov. 2022 08h37 HE
|
Brain & Behavior Research Foundation
New York, Nov. 28, 2022 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Warning Signs & What to Look for: Anxiety and Depression in Childhood”...
neurocare group AG Announces Publication Confirming the Importance of Sleep for Effectiveness of Combined rTMS and CBT for OCD
21 nov. 2022 10h00 HE
|
neurocare group AG
MUNICH, Nov. 21, 2022 (GLOBE NEWSWIRE) -- neurocare group AG ("neurocare" or the "Company"), a leading innovator in personalized mental health and performance empowering clinicians to deliver best...
GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
10 nov. 2022 07h05 HE
|
GH Research PLC
DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological...
Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute
25 oct. 2022 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 25 October 2022 at 9 AM (EEST) Nexstim Receives an NBT® System Order from Alamo Neurosurgical Institute Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces...
Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022
13 oct. 2022 16h50 HE
|
Biomerica, Inc.
Notice of Patent Allowance in Australia containing broad claims pertaining to treating ADD/ADHD using the InFoods® Technology Notice of Patent Allowance in Japan containing broad claims pertaining to...
Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022
10 oct. 2022 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
NeuroSigma Announces Receipt of Permanent HCPCS Codes from CMS for Monarch eTNS System
27 sept. 2022 12h00 HE
|
NeuroSigma, Inc.
LOS ANGELES, Sept. 27, 2022 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced that the Centers for Medicare & Medicaid Services ("CMS") has confirmed...